Infectious diseases of the lower respiratory tract
Conditions
Interventions
Experimental group:Ambroxol hydrochloride solution for inhalation is 3 ml/22.5 mg twice daily
Control group:Placebo (ambroxol hydrochloride solution matrix for inhalation), 3 ml twice daily
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. Patients with mucus sputum symptoms (sputum trait score =2 points) and difficulty in coughing up sputum (difficulty of coughing up sputum =2 points) with lower respiratory tract infections (such as acute onset of chronic bronchitis, pneumonia, acute exacerbation of chronic obstructive pulmonary disease, etc.); 2. Inpatients; 3. Age 18-79 years old, gender is not limited; 4. Voluntarily sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. Those who are allergic (those who are allergic to more than two types of substances) or those who are known to be allergic to the ingredients contained in the experimental drugs; 2. Patients with upper respiratory tract infection; 3. Patients with bronchial asthma, bronchiectasis and pulmonary interstitial fibrosis; 4. Patients with weakness to cough up sputum (such as long-term bed rest, advanced lung cancer, etc.); 5. Patients with severe primary diseases of cardiovascular and cerebrovascular, liver, kidney and hematopoietic system; 6. Patients with alcoholism and drug dependence, or patients with mental disorders; 7. Pregnant or lactating women or those planning to become pregnant (including men and women); 8. Those who have participated in or are participating in other clinical trials within 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sputum traits; | — |
Secondary
| Measure | Time frame |
|---|---|
| Difficulty in coughing up sputum;Sputum volume;cough; | — |
Countries
China
Contacts
Public ContactZhaolong Cao
Peking University People's Hospital
Outcome results
None listed